Clinical Holds in Early Oncology Drug Development

Alexandra Snyder, Dinesh De Alwis, Asthika Goonewardene, Priti S. Hegde
doi: https://doi.org/10.1101/2022.06.03.22275971

Article Information

doi 
https://doi.org/10.1101/2022.06.03.22275971
History 
  • June 6, 2022.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Alexandra Snyder, MD*,1,
  2. Dinesh De Alwis, PhD3,
  3. Asthika Goonewardene2 and
  4. Priti S. Hegde, PhD*,4
  1. 1Two River, Inc. 689 Fifth Ave, New York, NY 10022
  2. 2Truist Securities. 711 Fifth Ave, New York, NY 10022
  3. 3Early Oncology Development, Merck & Co., Inc., Rahway, NJ, USA
  4. 4Foundation Medicine. 150 Second Street, Cambridge, MA 02141
  1. ↵*Co-corresponding; email: snyderalex{at}gmail.com
Back to top
Posted June 06, 2022.
Download PDF
Data/Code
Email
Clinical Holds in Early Oncology Drug Development
Alexandra Snyder, Dinesh De Alwis, Asthika Goonewardene, Priti S. Hegde
medRxiv 2022.06.03.22275971; doi: https://doi.org/10.1101/2022.06.03.22275971
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area